ClinicalTrials.gg
RecruitingNCT05641844Updated Nov 13, 2025

A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal Fistulas

An interventional study of RD2 Ver.02 and Saline in Anal Fistula, sponsored by RedDress Ltd.. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-13.

Sponsored by RedDress Ltd. · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Rectal Fistula with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Rectal Fistula · United States.

Planned enrollment
5th of 15
110 · median 21
Started
2024
with 1 other
No phase
8 of 20
3 open now
Registered
13th of 20
by date
Lead sponsor
1 of 20
RedDress Ltd.

Among the 20 studies in Rectal Fistula with a site in United States, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 with no phase, and was the 13th registered.

Rectal Fistula

170 studies on the registry are indexed under Rectal Fistula; 45 are open to participants now.

Browse Rectal Fistula studies →

Open to participants now

7 of the 20 studies in Rectal Fistula with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Rectal Fistula studies recruiting now, 18 (69%) set no upper age limit and 7 (27%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Rectal Fistula with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assesses the safety of autologous RD2 Ver.02 as compared to a control for managing transsphincteric and intersphinsteric anal fistulas.

The main questions it aims to answer are:

Assess the safety and efficacy of RD2 Ver.02 in anal fistula application, compared to control.

Complication rate by 6 months of anal fistula treatment with RD2 Ver.02 compared to control.

Recurrence of anal fistula at 12 months post-treatment Incidence of perirectal infection by 6 months in anal fistulas treated with RD2 Ver.02 compared to control.

Patients will be randomized in to 2 arms. For all patients, blood will be drawn to ensure the blinding of the patients, the fistula will be evaluated and debrided, and then the internal fistula opening will be suture-closed, and a water leak test will be performed to ensure sealing. Following the water leak test, In the treatment arm, the patient's own coagulating blood will be applied into the entire fistula tract, allowing it to clot and serve as a provisional matrix inside the fistula tract. In the control arm, the blood sample will be discarded and saline will be applied to the fistula tract.

03

Conditions studied

  • Anal Fistula

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥18 years of age
  • Subject has a transsphincteric or long intersphincteric anal fistula (>1.5 cm), with a seton in place for a minimum of 1 month, deemed eligible for primary or repeat fistula repair by anorectal advancement flap or LIFT: Anterior, posterior or lateral fistula, first or recurrent, at any position circumferentially, with one external opening and one internal opening.
  • Subjects is unable or unwilling to receive invasive surgical procedures, anorectal advancement flap or LIFT procedure, and is opting for minimally invasive technique of anal fistula management (i.e., fistula tract debridement and suturing of internal opening).
  • 2.1.4 Prior to enrollment, during the preceding 3 months from Treatment Visit, subject must undergo a pelvic MRI to evaluate eligibility criteria unable to be assessed clinically.
  • Female subjects who are capable of conceiving and all males capable of insemination must use an acceptable form of in order to participate in the study and for 6 months following study procedure (acceptable forms of contraception include condoms for males and contraceptive pills or IUDs for women)

Exclusion criteria

Exclusion Criteria:

  • Subject who has a of less than 24 months.
  • Subjects who are cognitively impaired and have a healthcare proxy or those who are cognitively impaired and clearly do not understand the contents of the form.
  • Cannot withdraw blood in the required amount (up to 15 mL).
  • Women who are pregnant or currently breast feeding.
  • Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive systemic (more than 10mg per day).
  • Multiple fistula tracts, as confirmed on pelvic MRI
  • Short fistula tract that in the surgeon's opinion are amenable to fistulotomy
  • Active infection including perianal infection, and/or any active systemic or local infection.
  • Presence of a perirectal abscess on pelvic MRI
  • Presence of dominant luminal active Crohn's disease, validated by recent colonoscopy from preceding 12 months, requiring immediate therapy
  • Rectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.
  • Known allergies or to any of the following: antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast); Known hypersensitivity to reagents and components of RD2 Ver.02 including calcium gluconate, Kaolin or citrate and ethylene oxide.
  • to MRI scan, (e.g., due to the presence of pacemakers, hip replacements, or severe claustrophobia).
  • Known coagulation problems, abnormal level or if heparin is given intravenously. Subjects who are taking Coumadin, Aspirin, Plavix (Clopidogrel), Eliquis or Pradaxa will not be excluded.
  • Patients with increased risk for the surgical procedure or major alteration of any of the following laboratory tests:

    1. Serum Creatinine levels >1.5 times the upper limit of normality ()
    2. Total >1.5 times the ULN (unless predominantly non conjugated due to documented history of Gilbert's syndrome)
    3. / ALT >3.0 times the ULN
    4. \<10.0 g/dL
    5. Platelets \<150.0 x109/L
    6. Albuminemia \<3.0 g/dL.
  • Patients who do not wish to or cannot comply with study procedures.
  • Patients currently receiving or having received within 12 months prior to enrolment into this clinical study, any drug.
  • Subjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.
  • Contraindication to the anesthetic procedure.
  • Subject with a diagnosis of Ulcerative Colitis
  • Subject with , undergoing active treatment
  • Rectovaginal fistula
  • History of pelvic radiation
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Other
    Treatment arm

    Subjects will undergo debridement of the fistula tract and suturing of internal opening, followed by a. water leak test. RD2 Ver.02 will be applied to the fistula tract in the operating room.

    Device: RD2 Ver.02 · Other: Saline

  • Other
    Control arm

    Subjects will undergo debridement of the fistula tract and suturing of internal opening, followed by a. water leak test. Saline will be applied to the fistula tract in the operating room.

    Other: Saline

Interventions

  • DeviceRD2 Ver.02

    Debridement and suturing of the internal opening of the anal fistula and RD2 Ver.02 coagulating blood application into the fistula tract with a semi flexible cannula.

  • OtherSaline

    Debridement and suturing of the internal opening of the anal fistula and Saline administration into the fistula tract with a semi flexible cannula.

06

What researchers measure

Primary outcomes

  1. Combined healing rate at 6 months of anal fistulas treated with RD2 Ver.02 compared to control

    Fistula healing will be assessed by both a blinded clinical assessor and confirmation by MRI. Healing clinical assessment is defined as the absence of any anal symptom, with no discharge from the fistula and a closed external opening. Results will be confirmed by central blinded MRI assessment.

    Time frame: 6 months after anal fistula treatment per subject

Secondary outcomes

  1. Clinical recurrence of anal fistula at 12 months post-treatment in subjects with clinically healed fistula at 6 months, treated with RD2 Ver. 02 compared to control, to evaluate the long-term efficacy of RD2 Ver.02 Application.

    Assessed by the blinded clinical assessor for fistula recurrence 12 months post procedure

    Time frame: 12 months

  2. Incidence of perirectal infection by 6 months in anal fistulas treated with RD2 Ver.02 compared to control.

    Infection assessment of the anal fistula

    Time frame: 6 months

Other outcomes

  1. Incidence of device-related adverse events in patients treated with RD2 Ver.02

    Overall incidence and severity of Adverse Events (AEs) in RD2 Ver.02 treatment group

    Time frame: 12 months

  2. Incidence of adverse events compared between RD2 Ver.02 and control arms

    Comparison of the AEs between RD2 Ver.02 and control treatment groups

    Time frame: 12 months

07

Study locations

9 of 10 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

Of 58 interventional studies with no phase under Rectal Fistula, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 38. This study's planned 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2022
First posted
Dec 8, 2022
StartActual
Jan 20, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Nov 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05641844
Lead sponsor
RedDress Ltd.
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Jan 20, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 13, 2025

Study contacts

Sharon Sirota
Contact
sharon@reddress.co.il
+972-54-580-0765
Alon Kushnir
Contact
alon@reddress.co.il
+972-50-630-6312

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion